The effectiveness of RIA therapy cancer thyroid Doses 30 mCi , 50 mCi: Internal Dosemetry in for low risk

RIA therapy is crucial for treating thyroid disorders, specifically thyroid cancer. This study aims to evaluate the efficacy of 30 mCi and 50 mCi RIA therapy doses in low-risk papillary thyroid carcinoma patients post-thyroidectomy, based on their thyroglobulin levels. In order to achieve this goal, we have carefully analyzed and evaluated the thyroglobulin levels before and after radioiodine treatment while also examining the values from different viewpoints. In our thorough analysis, we found that about 90% of study participants experienced positive outcomes, indicating a high success rate. The study shows that both RIA therapy doses effectively reduced thyroglobulin levels in low-risk papillary thyroid carcinoma patients post-thyroidectomy. This provides insights into the optimal therapy dosage for this patient group. This approach should take into consideration the differences between patients, such as absorption rate and the specific state of the patient, in order to ensure a balance between therapeutic efficacy and radioexposure.